Jain Amita, Mondal Rajesh
Post Graduate Department of Microbiology, King George's Medical University, Lucknow, India.
Indian J Med Res. 2007 Jan;125(1):89-94.
BACKGROUND & OBJECTIVE: Extended spectrum beta-lactamase (ESBL) producing Klebsiella spp led to serious concern about septicaemic neonates in neonatal intensive care units (NICU) due to high resistance against commonly used antimicrobial agents. Knowledge of disease burden and information on resistance to antimicrobials are required for proper management of such cases in NICUs. Here we report the prevalence and resistance pattern of ESBL producing Klebsiella spp isolated from cases of neonatal septicaemia at a tertiary care hospital from north India.
A total of 100 clinical isolates of Klebsiella spp isolated from 2995 blood samples of suspected cases of neonatal septicaemia were studied. Antimicrobial susceptibility was determined by Kirby- Bauer's disc diffusion method. All isolates were screened for ESBL production on the basis of inhibition zone against cephotaxime (<27 mm) and ceftazidime (<22 mm) and a breakpoint of minimum inhibitory concentration (MIC) (<2 microg/ml for cephotaxime and <8 microg/ml for cefpodoxime) by agar dilution method. Resistance pattern of ESBL producers and non-ESBL producers was compared.
Of the 100 Klebsiella isolates, 58 were positive for ESBL production, which was much lower than 86.6 per cent reported in 2003. Almost all the isolates were sensitive to imipenam and meropenam. Drug resistance was found to be significantly more common in ESBL producing isolates than in non-ESBL producers.
INTERPRETATION & CONCLUSION: We found that 56 per cent of Klebsiella spp isolates were ESBL producers. There is a need to carefully formulate therapeutic strategies to control infections in NICUs. The high percentage of drug resistance in ESBL producing Klebsiella spp suggests that routine detection of ESBL is required by reliable laboratory methods.
产超广谱β-内酰胺酶(ESBL)的克雷伯菌属因对常用抗菌药物具有高度耐药性,引发了新生儿重症监护病房(NICU)对败血症新生儿的严重关注。为了在NICU中妥善管理此类病例,需要了解疾病负担以及抗菌药物耐药性信息。在此,我们报告了从印度北部一家三级医院的新生儿败血症病例中分离出的产ESBL克雷伯菌属的流行情况和耐药模式。
对从2995份疑似新生儿败血症病例的血样中分离出的100株克雷伯菌属临床分离株进行了研究。采用 Kirby - Bauer 纸片扩散法测定抗菌药物敏感性。根据琼脂稀释法测定的头孢噻肟(<27 mm)和头孢他啶(<22 mm)的抑菌圈以及最低抑菌浓度(MIC)断点(头孢噻肟<2 μg/ml,头孢泊肟<8 μg/ml),对所有分离株进行ESBL产生情况的筛选。比较了产ESBL菌株和非产ESBL菌株的耐药模式。
在100株克雷伯菌分离株中,58株产ESBL呈阳性,这远低于2003年报告的86.6%。几乎所有分离株对亚胺培南和美罗培南敏感。发现产ESBL的分离株中的耐药情况比非产ESBL的分离株显著更常见。
我们发现56%的克雷伯菌属分离株是ESBL生产者。需要仔细制定治疗策略以控制NICU中的感染。产ESBL克雷伯菌属中高比例的耐药性表明需要通过可靠的实验室方法进行ESBL的常规检测。